Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Luke who wrote (619)	5/12/1998 9:06:00 PM
From: Platter	Respond to of 3202

Vector Securities International upgraded to buy from attractive its rating for INCYTE PHARMACEUTICALS INC based on strong fundamentals and a weak stock price. The share price of Incyte had fallen earlier today on competitive concerns after a report that Perkin-Elmer Corp. was entering a venture to accelerate a project to fully map human DNA, Vector said in a research note. Incyte is a biotech company that designs and markets genomic database products for use in drug development. (Reuters

To: Luke who wrote (619)	5/13/1998 8:46:00 PM
From: jbershad	Respond to of 3202

Luke please explainn what an EST is. Jerry

To: Luke who wrote (619)	5/13/1998 9:16:00 PM
From: jbershad	Read Replies (1) \| Respond to of 3202

To answer your question, yes partial sequencing patents at present are allowed. (EST?) If you read the Lehman article it is pretty complicated. Yes, what scope will be given <by the courts later on.> I hold the stock and feel HGSI and INCY will have good growth for years to come. At this stage I would like to see if the PKN "VENTURE" works out. My impression is HGSI and INCY have enough to overwhelm Venture. I hope the 2 wall street analysts don't jump out of a window in a few years. Jerry